News

NPUK's Annual Family Conference & Interactive Workshop goes digital

An update regarding the NPUK Annual Family Conference & Interactive Workshop 2020.

Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics to Hold Call for Patients and Investors Wednesday, May 20 at 4:30 pm EDT

Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

Company reported in March 2020 that FDA had also provided positive feedback on the pivotal trial design...

Cyclo Therapeutics Closes $2.0 Million Private Placement

ALACHUA, FL – (BusinessWire) – April 27, 2020 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors...